SOUTH SAN FRANCISCO, Calif., February 04, 2025--SiteOne Therapeutics Announces Positive Phase 1 Clinical Data for STC-004, a Novel NaV1.8 Inhibitor in Development for Non-Opioid Pain Treatment ...

Like Vertex's Journavx (suzetrigine), cleared by the FDA in February for moderate-to-severe acute pain, STC-004 is an oral inhibitor of the NaV1.8 sodium channel, blocking a pain-signalling ...

STC-004 works by blocking the Nav1.8 sodium channel, a voltage-gated channel primarily found in pain-sensing neurons. The asset could have a lucrative market potential, given that it is not opioid ...

Eli Lilly and Co. announced plans on Tuesday to acquire private biotechnology company San Francisco-based SiteOne Therapeutics Inc. in a deal worth up to $1 billion. SiteOne, founded in 2010, is ...

SiteOne’s STC-004 is an oral small molecule designed to target NaV1.8. In February, SiteOne reported Phase 1 results showing STC-004 was rapidly absorbed with a half-life that supports once ...

SiteOne’s drug candidate, STC-004, is on track to begin Phase 2 testing. SiteOne develops drugs that target sodium channels, which are found primarily in the peripheral nervous system.

The acquisition centers on SiteOne’s STC-004, a Phase 2-ready Nav1.8 inhibitor designed to provide relief for chronic pain sufferers without the risks of addiction associated […] ...

Lilly’s sights are set on STC-004, a sodium channel inhibitor made to block NaV1.8, an ion channel primarily found in the peripheral nervous system and involved in pain sensation.

Perhaps STC-004 will flop in upcoming clinical trials. But there's something important to highlight about Eli Lilly that this acquisition brings to light. Beyond the weight management market ...

Called STC-004, the treatment is a a Nav1.8 inhibitor that is ready for Phase 2 testing. Lilly said STC-004 might represent a next-generation, non-opioid treatment for chronic pain.

In February, SiteOne announced positive results from an early-stage study on STC-004, which showed that the drug was safe and well-tolerated at all dose levels while also improving pain tolerance.